KCTD6

Across TCGA pan-cancer cohorts, KCTD6 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of KCTD6’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where KCTD6 RNA is repressed in tumor relative to normal tissue. In most cancer types KCTD6 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, LIHC, and KIRC are the cancer types where KCTD6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KCTD6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	IV	−1.306	<.001	9	view →
LIHC	All	III,IV	+1.149	<.001	9	view →
KIRC	Male	All	−0.636	<.001	8	view →
HNSC	Male	II,III,IV	−0.564	<.001	8	view →
COAD	Male	II,III,IV	+0.562	<.001	7	view →
LUSC	All	All	−0.355	<.001	7	view →
BRCA	All	III,IV	+1.064	<.001	6	view →
KIRP	All	All	−0.335	.006	6	view →
LUAD	All	All	+0.299	<.001	5	view →
KICH	All	All	−0.654	.001	4	view →
UCEC	All	All	−0.400	.035	2	view →
PRAD	All	All	−0.219	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

KCTD6–THCA

Open the THCA breakdown →